[177Lu]Lu-DOTATOC外渗:病例报告与讨论
本文报告一例神经内分泌肿瘤肽受体放射性核素治疗中[177Lu]Lu-DOTATOC外渗的病例,采用运动、抬高患肢、加压包扎和加热的处理策略,通过全身显像、定量SPECT/CT和接触剂量率测量验证药物再分布;[177Lu]Lu-DOTATOC在1天内再分布至肿瘤和器官,患者无不适及外渗相关副作用,剂量学显示肾脏和肿瘤吸收剂量与后续治疗周期相似。
要点
- 外渗后采用运动、抬高患肢、加压包扎和加热处理,药物在1天内再分布至肿瘤和器官。
- 通过接触注射部位皮肤剂量率测量可简便验证药物再分布。
- 剂量学评估显示无需改变治疗方案以补偿可能不完整的治疗。
核心结论
- 外渗处理成功,通过测量接触皮肤剂量率可简便验证药物再分布;剂量学结果表明无需改变治疗疗程以补偿外渗可能导致的不完整治疗。
研究设计与样本
- 病例报告:一例[177Lu]Lu-DOTATOC外渗的神经内分泌肿瘤患者,采用运动、抬高患肢、加压包扎和加热处理,并通过全身显像、定量SPECT/CT和接触剂量率测量进行验证。
主要发现
- [177Lu]Lu-DOTATOC在1天内再分布至肿瘤和器官。
- 患者住院期间及之后未报告任何不适,未观察到外渗相关副作用。
- 后续治疗周期的定量SPECT/CT分析显示,两次治疗在肾脏和肿瘤吸收剂量方面相似。
- 注射部位附近表皮基底层的辐射剂量估计值与缺乏副作用相一致。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the case of extravasation of radioactive drugs used in peptide-receptor radionuclide therapy of neuroendocrine tumors, or in radionuclide therapy in general, rapid action is important to reduce or avoid complications. The literature on extravasation of drugs for radionuclide therapy is sparse. Based on the present case, we discuss handling and consequences of extravasation. Further, we demonstrate that dosimetry can aid in judging if the treatment of neuroendocrine tumors is satisfactory even after extravasation. CASE PRESENTATION: A case of extravasation of [177Lu]Lu-DOTATOC with a treatment strategy involving exercise and elevation of the affected arm and application of a compression bandage and heating is reported. Redistribution of the drug is verified and quantified by whole-body imaging and quantitative SPECT/CT and measurements of the dose rate at contact with the injection site. [177Lu]Lu-DOTATOC was redistributed to tumors and organs within 1 day. The patient did not report any discomfort during or after hospitalization, and no side effects related to extravasation were observed. Quantitative SPECT/CT scans at the subsequent treatment cycle of the same patient were analyzed for a comparison between the treatments. Dosimetry showed the treatments were similar with respect to the kidney and tumor absorbed doses. The radiation dose to the epidermal basal layer near the injection site was estimated and found to be consistent with the lack of side effects. CONCLUSIONS: The treatment of extravasation was successful, and the redistribution of the drug can be easily verified through measurement of the dose rate at contact with the skin. From the results of dosimetry, it was assessed that no change of the treatment course was necessary to compensate for a possibly incomplete treatment as a result of the extravasation.
引用
- Arveschoug AK, Bekker AC, Iversen P, et al. Extravasation of [177Lu]Lu-DOTATOC: case report and discussion. EJNMMI Res. 2020. PMID: 32577838. doi:10.1186/s13550-020-00658-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。